Company news
Precigen, Inc. news in 2021
Precigen, Inc.'s news releases, calls and decks from 2021, newest first.
Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia
December 12, 2021
Precigen to Present at the Stifel 2021 Virtual Healthcare Conference
November 9, 2021
Precigen Achieves Significant Clinical Progress for UltraCAR-T® and AdenoVerse™ Therapies
November 3, 2021
Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical Developments
October 26, 2021
Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors
October 25, 2021
Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer
October 11, 2021
Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
September 30, 2021
Precigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and the H.C. Wainwright 23rd Annual Global Investment Conference
August 31, 2021
Precigen Reports Second Quarter and First Half 2021 Financial Results
August 8, 2021
Precigen to Announce Second Quarter and First Half 2021 Financial Results on August 9th
August 1, 2021
Precigen to Present at the JMP Securities Life Sciences Conference
June 9, 2021
Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
June 9, 2021
Precigen Reports First Quarter 2021 Financial Results
May 9, 2021
Precigen Announces Departure of Chief Financial Officer
March 29, 2021
Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
March 22, 2021
Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
March 17, 2021
Precigen Reports Fourth Quarter and Full Year 2020 Financial Results
February 28, 2021
Precigen to Announce Fourth Quarter and Full Year 2020 Financial Results on March 1st
February 21, 2021
Precigen to Participate in Guggenheim Healthcare Talks Oncology Day
February 3, 2021
Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
January 25, 2021
Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock
January 21, 2021
Precigen Announces Proposed Public Offering of Common Stock
January 20, 2021
Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare Conference
January 12, 2021
Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021
Precigen Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
January 4, 2021
Calls in 2021
Decks in 2021
- 39th Annual J.P. Morgan Healthcare Conference (January 2021)
Conference · 23 slides · Jan 13, 2021